CA2478145A1 - Formulations and methods of using nitric oxide mimetics in cancer treatment - Google Patents

Formulations and methods of using nitric oxide mimetics in cancer treatment Download PDF

Info

Publication number
CA2478145A1
CA2478145A1 CA002478145A CA2478145A CA2478145A1 CA 2478145 A1 CA2478145 A1 CA 2478145A1 CA 002478145 A CA002478145 A CA 002478145A CA 2478145 A CA2478145 A CA 2478145A CA 2478145 A1 CA2478145 A1 CA 2478145A1
Authority
CA
Canada
Prior art keywords
nitric oxide
cancer
cells
tumor
mimetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002478145A
Other languages
English (en)
French (fr)
Inventor
Charles H. Graham
Lynne-Marie Postovit
Michael A. Adams
Jeremy P. W. Heaton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University at Kingston
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2478145A1 publication Critical patent/CA2478145A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002478145A 2002-03-06 2003-03-06 Formulations and methods of using nitric oxide mimetics in cancer treatment Abandoned CA2478145A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36296902P 2002-03-06 2002-03-06
US60/362,969 2002-03-06
US36262002P 2002-03-07 2002-03-07
US60/362,620 2002-03-07
PCT/CA2003/000313 WO2003074082A1 (en) 2002-03-06 2003-03-06 Formulations and methods of using nitric oxide mimetics in cancer treatment

Publications (1)

Publication Number Publication Date
CA2478145A1 true CA2478145A1 (en) 2003-09-12

Family

ID=27791719

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002478145A Abandoned CA2478145A1 (en) 2002-03-06 2003-03-06 Formulations and methods of using nitric oxide mimetics in cancer treatment

Country Status (5)

Country Link
EP (1) EP1492567A1 (https=)
JP (1) JP2005527510A (https=)
AU (1) AU2003208228A1 (https=)
CA (1) CA2478145A1 (https=)
WO (1) WO2003074082A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
DE602005027461D1 (de) 2004-04-21 2011-05-26 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
WO2005120493A1 (en) * 2004-06-10 2005-12-22 Tohoku University Anticancer effect enhancer
WO2006018088A1 (en) * 2004-08-19 2006-02-23 Switch Biotech Ag Use of a pde 5 inhibitor for treating and preventing hypopigmentary disorders
ATE438403T1 (de) * 2004-08-19 2009-08-15 Switch Biotech Llc Verwendung eines pde5-hemmers zur behandlung und vorbeugung von hypopigmentierungsstörungen
AU2012203798B2 (en) * 2005-08-12 2013-11-07 Northrop Grumman Systems Corporation O-nitro compounds, pharmaceutical compositons thereof and uses thereof
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
WO2009086470A2 (en) * 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide - donating compounds and uses thereof
JP5467259B2 (ja) * 2008-03-13 2014-04-09 国立大学法人 千葉大学 シスプラチン効果増強剤及び抗癌剤キット
AU2009244790B2 (en) * 2008-05-09 2013-09-12 Duke University Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
EP3189835B1 (en) * 2011-02-28 2018-07-25 National Cerebral and Cardiovascular Center Medical agent for suppressing malignant tumor metastasis
JP5842367B2 (ja) * 2011-04-07 2016-01-13 ニプロ株式会社 抗癌剤増感剤
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CN106572988B (zh) 2014-04-08 2022-04-08 卫理公会医院 Inos抑制性组合物及其作为乳腺癌治疗剂的用途
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
JP6993961B2 (ja) 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
KR20240160671A (ko) 2016-04-01 2024-11-11 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3464573B1 (en) 2016-06-06 2026-03-04 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
ES2972119T3 (es) 2018-08-10 2024-06-11 Alexion Pharma Inc Cicatrización ósea en implantes utilizando fosfatasa alcalina
KR20220111693A (ko) 2019-12-09 2022-08-09 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제 폴리펩티드 및 이의 이용 방법
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CN114869894A (zh) * 2022-05-10 2022-08-09 福州大学 一种小分子化合物在制备作为尿激酶受体抑制剂药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV11542B (en) * 1995-03-30 1997-02-20 Latvijas Organiskas Sintezes Instituts Substituted 1,3,9,11-tetraoxa-4,5,7,8-tetraazaundecadien-4,7-dioxides-5,7, preparation and use thereof
AU8398398A (en) * 1997-07-14 1999-02-10 Brigham And Women's Hospital Modification of nitric oxide activity to treat fas-induced pathologies
JP2004508279A (ja) * 2000-01-26 2004-03-18 シーダース　シナイ　メディカル　センター 薬剤を異常脳領域及び／又は悪性腫瘍にデリバリーするためにカリウムチャンネル活性化を用いる方法
US20010038832A1 (en) * 2000-04-11 2001-11-08 Benjamin Bonavida Nitric oxide and analogues thereof effectuate sensitization of neoplasm and immunologically undesired tissues to cytotoxicity
JP2003531179A (ja) * 2000-04-26 2003-10-21 クイーンズ ユニバーシティ アット キングストン 悪性細胞表現型に対し一酸化窒素模倣体を使用する処方および方法

Also Published As

Publication number Publication date
WO2003074082A1 (en) 2003-09-12
AU2003208228A1 (en) 2003-09-16
JP2005527510A (ja) 2005-09-15
EP1492567A1 (en) 2005-01-05

Similar Documents

Publication Publication Date Title
US8168232B2 (en) Formulations and methods of using nitric oxide mimetics in cancer treatment
CA2478145A1 (en) Formulations and methods of using nitric oxide mimetics in cancer treatment
US6946484B2 (en) Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20050142217A1 (en) Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
AU2001250221A1 (en) Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US6689787B1 (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
AU2013208649B2 (en) Combination therapy for the treatment of cancer
EP1502604A1 (en) Use of nitric oxide mimetics in cancer treatment
US20190358229A1 (en) Pac-1 combination therapy
KR100858946B1 (ko) 초기 유방암을 가진 폐경후 여성의 치료를 위한아나스트로졸의 용도
US20220323474A1 (en) Drug combination treatments using bone-targeting therapeutics for bone and bone-related disease
EP2432480B1 (en) Compositions and methods for treating inflammatory arthritis
US20220409582A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
RU2776995C2 (ru) Виды комбинированной лекарственной терапии с использованием лекарственных препаратов, целенаправленно воздействующих на костную ткань, для лечения костей и заболевания, связанного с костной тканью
TW202128213A (zh) 一種用於緩解癌症化療引起抗藥性並對化療增效之醫藥組合物及其用途
JP2002524481A (ja) 他の抗癌剤または理学療法と組み合わせたスクアラミンを使用する癌腫の処置
JP2002524481A5 (https=)
WO2011056663A1 (en) Method of treating cancer using combination of a bifunctional alkylating agent and dna repair inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead